Citigroup Issues Pessimistic Forecast for Stevanato Group (NYSE:STVN) Stock Price

Stevanato Group (NYSE:STVN) had its target price lowered by stock analysts at Citigroup from $32.00 to $26.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on STVN. KeyCorp reduced their price target on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday. Jefferies Financial Group set a $17.50 price objective on Stevanato Group in a research report on Tuesday, February 10th. Weiss Ratings restated a “hold (c)” rating on shares of Stevanato Group in a report on Monday, December 29th. Wall Street Zen downgraded shares of Stevanato Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Morgan Stanley initiated coverage on shares of Stevanato Group in a research note on Monday, December 1st. They issued an “equal weight” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Stevanato Group Stock Down 2.8%

Shares of NYSE:STVN opened at €15.46 on Thursday. The firm has a market capitalization of $4.68 billion, a P/E ratio of 26.66, a P/E/G ratio of 1.46 and a beta of 0.57. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.30 and a current ratio of 1.76. The stock has a 50 day moving average price of €17.58 and a 200-day moving average price of €21.66. Stevanato Group has a 52-week low of €13.91 and a 52-week high of €28.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada increased its position in shares of Stevanato Group by 10.8% during the first quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock valued at $8,930,000 after acquiring an additional 42,731 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Stevanato Group by 4.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 170,002 shares of the company’s stock valued at $4,153,000 after acquiring an additional 7,232 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in Stevanato Group by 14.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,833 shares of the company’s stock valued at $94,000 after purchasing an additional 497 shares during the last quarter. Marco Investment Management LLC purchased a new stake in Stevanato Group during the 2nd quarter valued at $228,000. Finally, Zions Bancorporation National Association UT increased its holdings in shares of Stevanato Group by 9.2% in the 2nd quarter. Zions Bancorporation National Association UT now owns 102,357 shares of the company’s stock worth $2,501,000 after purchasing an additional 8,648 shares in the last quarter.

Stevanato Group News Roundup

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Q4 beats and revenue momentum — Stevanato reported Q4 results that beat expectations (reported EPS ~$0.2114 vs. ~$0.20 consensus) and highlighted strong revenue growth, reinforcing demand for its pharmaceutical packaging and high‑value solutions. STVN Q4 Highlights
• Positive Sentiment: 2026 guidance and HVS mix — Management outlined a 2026 revenue target up to €1.308B and expects high‑value solutions (HVS) to reach ~48% of sales, supporting margin expansion potential as capex is mainly HVS‑directed. 2026 Revenue Target Article
• Positive Sentiment: Analyst buy support — At least one note (Seeking Alpha piece) reiterates a Buy thesis citing Q4/FY25 strength and long‑term demand drivers, framing current weakness as cyclical in the Engineering segment. Stevanato: Strong Q4 Results Reinforce Long-Term Growth Story
• Neutral Sentiment: Earnings call detail — Full Q4/FY25 earnings call transcripts and summaries are available for deeper read; they provide management color on capex allocation (heavy toward HVS) and the cyclical pressure in Engineering. Useful for modeling near‑term margin recovery timing. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Transcripts published — Full call transcripts (Seeking Alpha / InsiderMonkey) confirm the beat and provide verbatim management commentary for investors building scenarios. Earnings Call Transcript
• Negative Sentiment: Multiple analyst price‑target cuts — Morgan Stanley cut its PT to $19 and moved to Equal Weight; Citigroup lowered its PT to $26 (maintained Buy); KeyCorp trimmed its PT to $32 (keeps Overweight). Those revisions reduce near‑term upside expectations and likely contributed to selling pressure. Analyst PT Changes (Benzinga) KeyBanc / StreetInsider

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.